Certains éléments peuvent ne pas apparaître en raison des règles de confidentialité.
Veuillez mettre à jour vos critères de recherche et essayer à nouveau
A panel discussion by the experts will be followed by a Q&A session. Submit your questions: https://bit.ly/question-submission
The Regional Verification Commission (RVC) for Measles and Rubella Elimination in the WHO Eastern Mediterranean Region (EMRO) declared that measles and rubella have been eliminated in Bahran, Iran, Oman and Egypt.
RVC hosted the 4th regional meeting on 1 - 3 November 2022.
The meeting had three objectives, mainly focused around reviewing:
- The progress reports on elimination status of measles and rubella for countries already verified by the RVC (Bahrain, Iran, and Oman)
- The second version of the primary verification report on elimination status of measles and rubella in Egypt
- The status of measles and rubella elimination in the Eastern Mediterranean region.
Meeting participants included the National Verification Committees (NVCs), representatives of respective national immunisation programmes, the Director of department of communicable disease and IVP unit at EMRO, and WHO headquarters.
Based on follow-up discussions with the NVC and country teams, the RVC members reached the consensus on elimination status of the following countries:
- Bahrain, Iran, and Oman sustained their elimination status for measles and rubella for the period of 2018 – 2020;
- Egypt interrupted endemic transmission of measles and rubella virus and accordingly verified that measles and rubella had been eliminated from the country for the period 2018 – 2021.
The RVC members congratulated the four countries and IVP Secretariat for the remarkable achievements demonstrated by the evidence, especially the as two most-populated countries in the region (Egypt and Iran) also faced the challenges of the COVID-19 pandemic, and encouraged to all states maintain the status of measles and rubella elimination.
Measles and rubella vaccines are safe and effective, however, achieving equitable coverage, particularly for the second dose of measles containing vaccine (MCV2) is well below the 95% target of immunized children. Consequently, there were over 140,000 deaths globally, in 2018. Novel and improved vaccine delivery platforms such as microarray patches (MAPs) are needed to address the increasing challenge of achieving and sustaining effective vaccination of MRVs, to achieve the eradication of measles and rubella, a goal set by the WHO and partners. MAPs offer competitive advantages over needle and syringe (NS) vaccine delivery. They have a potential to be more thermostable and freeze resistant, do not require reconstitution resulting in an improved safety profile, they are easier to use, do not contain sharps, and are more acceptable by caregivers and vaccinees.
Measles and rubella MAPs (MR-MAPs) will soon enter phase one clinical trials and although early in development, critical actions are needed to prepare the pathway for late stage product development and mitigate against delays in scale up. The lack of a clear demand forecast for MR-MAP has been identified as significant bottleneck in the investment of this urgently needed innovative vaccine. In order to address this, the WHO is working with public health stakeholders at the country level to assess how MR-MAPs will be used, the critical product attributes that are required for use to achieve impact, and the potential demand for such products.
Presenter: Mateusz Hasso-Agopsowicz (WHO)
Registration link: https://who.zoom.us/meeting/register/tJYldeutrjosEtxl1XHL3q2PGmzFoy4klUcd